Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796275 | 1.00 | PRCP (0.71) | PRCPOPRM1GAAHTR2AHTR2C | |
| SCHEMBL1738261 | 0.92 | PRCP (0.83) | PRCPGAAHTR2AHTR2CHTR2B | |
| SCHEMBL28083503 | 0.85 | PRCP (0.90) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL3865487 | 0.85 | PRCP (0.97) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL29768302 | 0.83 | PRCP (1.00) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL2793867 | 0.83 | PRCP (1.00) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL2795999 | 0.83 | PRCP (1.00) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL1011373 | 0.83 | PRCP (1.00) | PRCPOPRM1GAAMEN1SLC22A1 | |
| Hydrochloric Acid SCHEMBL2790424 | 0.82 | PRCP (0.97) | PRCPOPRM1GAAMEN1SLC22A1 | |
| SCHEMBL30032724 | 0.81 | PRCP (0.71) | PRCPOPRM1GAAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149560-B1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | PRCP 3639/4885OPRM1 16/4885GAA 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.